-
Je něco špatně v tomto záznamu ?
Chitosan-based nanoscale systems for doxorubicin delivery: Exploring biomedical application in cancer therapy
M. Ashrafizadeh, K. Hushmandi, S. Mirzaei, S. Bokaie, A. Bigham, P. Makvandi, N. Rabiee, VK. Thakur, AP. Kumar, E. Sharifi, RS. Varma, AR. Aref, M. Wojnilowicz, A. Zarrabi, H. Karimi-Maleh, NH. Voelcker, E. Mostafavi, G. Orive
Status neindexováno Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, přehledy
NLK
Directory of Open Access Journals
od 2016
Free Medical Journals
od 2016
PubMed Central
od 2016
Europe PubMed Central
od 2016
ProQuest Central
od 2016-03-01
Open Access Digital Library
od 2016-03-01
Wiley-Blackwell Open Access Titles
od 2016
ROAD: Directory of Open Access Scholarly Resources
od 2016
PubMed
36684100
DOI
10.1002/btm2.10325
Knihovny.cz E-zdroje
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
Green chemistry has been a growing multidisciplinary field in recent years showing great promise in biomedical applications, especially for cancer therapy. Chitosan (CS) is an abundant biopolymer derived from chitin and is present in insects and fungi. This polysaccharide has favorable characteristics, including biocompatibility, biodegradability, and ease of modification by enzymes and chemicals. CS-based nanoparticles (CS-NPs) have shown potential in the treatment of cancer and other diseases, affording targeted delivery and overcoming drug resistance. The current review emphasizes on the application of CS-NPs for the delivery of a chemotherapeutic agent, doxorubicin (DOX), in cancer therapy as they promote internalization of DOX in cancer cells and prevent the activity of P-glycoprotein (P-gp) to reverse drug resistance. These nanoarchitectures can provide co-delivery of DOX with antitumor agents such as curcumin and cisplatin to induce synergistic cancer therapy. Furthermore, co-loading of DOX with siRNA, shRNA, and miRNA can suppress tumor progression and provide chemosensitivity. Various nanostructures, including lipid-, carbon-, polymeric- and metal-based nanoparticles, are modifiable with CS for DOX delivery, while functionalization of CS-NPs with ligands such as hyaluronic acid promotes selectivity toward tumor cells and prevents DOX resistance. The CS-NPs demonstrate high encapsulation efficiency and due to protonation of amine groups of CS, pH-sensitive release of DOX can occur. Furthermore, redox- and light-responsive CS-NPs have been prepared for DOX delivery in cancer treatment. Leveraging these characteristics and in view of the biocompatibility of CS-NPs, we expect to soon see significant progress towards clinical translation.
Bioaraba NanoBioCel Research Group Vitoria Gasteiz Spain
Biorefining and Advanced Materials Research Center Scotland's Rural College Edinburgh UK
Department of Chemical Engineering Quchan University of Technology Quchan Iran
Department of Medicine Stanford University School of Medicine Stanford California USA
Institute of Polymers Composites and Biomaterials National Research Council Naples Italy
Istituto Italiano di Tecnologia Center for Materials Interfaces Pontedera Pisa Italy
Monash Institute of Pharmaceutical Sciences Parkville Victoria Australia
NanoBioCel Research Group School of Pharmacy University of the Basque Country Vitoria Gasteiz Spain
School of Engineering Macquarie University Sydney New South Wales Australia
School of Engineering University of Petroleum and Energy Studies Dehradun Uttarakhand India
Singapore Eye Research Institute Singapore
Stanford Cardiovascular Institute Stanford University School of Medicine Stanford California USA
University Institute for Regenerative Medicine and Oral Implantology UIRMI Vitoria Gasteiz Spain
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23003276
- 003
- CZ-PrNML
- 005
- 20230421100148.0
- 007
- ta
- 008
- 230413s2023 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1002/btm2.10325 $2 doi
- 035 __
- $a (PubMed)36684100
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Ashrafizadeh, Milad $u Faculty of Engineering and Natural Sciences Sabanci University, Üniversite Caddesi Tuzla, Istanbul Turkey
- 245 10
- $a Chitosan-based nanoscale systems for doxorubicin delivery: Exploring biomedical application in cancer therapy / $c M. Ashrafizadeh, K. Hushmandi, S. Mirzaei, S. Bokaie, A. Bigham, P. Makvandi, N. Rabiee, VK. Thakur, AP. Kumar, E. Sharifi, RS. Varma, AR. Aref, M. Wojnilowicz, A. Zarrabi, H. Karimi-Maleh, NH. Voelcker, E. Mostafavi, G. Orive
- 520 9_
- $a Green chemistry has been a growing multidisciplinary field in recent years showing great promise in biomedical applications, especially for cancer therapy. Chitosan (CS) is an abundant biopolymer derived from chitin and is present in insects and fungi. This polysaccharide has favorable characteristics, including biocompatibility, biodegradability, and ease of modification by enzymes and chemicals. CS-based nanoparticles (CS-NPs) have shown potential in the treatment of cancer and other diseases, affording targeted delivery and overcoming drug resistance. The current review emphasizes on the application of CS-NPs for the delivery of a chemotherapeutic agent, doxorubicin (DOX), in cancer therapy as they promote internalization of DOX in cancer cells and prevent the activity of P-glycoprotein (P-gp) to reverse drug resistance. These nanoarchitectures can provide co-delivery of DOX with antitumor agents such as curcumin and cisplatin to induce synergistic cancer therapy. Furthermore, co-loading of DOX with siRNA, shRNA, and miRNA can suppress tumor progression and provide chemosensitivity. Various nanostructures, including lipid-, carbon-, polymeric- and metal-based nanoparticles, are modifiable with CS for DOX delivery, while functionalization of CS-NPs with ligands such as hyaluronic acid promotes selectivity toward tumor cells and prevents DOX resistance. The CS-NPs demonstrate high encapsulation efficiency and due to protonation of amine groups of CS, pH-sensitive release of DOX can occur. Furthermore, redox- and light-responsive CS-NPs have been prepared for DOX delivery in cancer treatment. Leveraging these characteristics and in view of the biocompatibility of CS-NPs, we expect to soon see significant progress towards clinical translation.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Hushmandi, Kiavash $u Department of Food Hygiene and Quality Control, Division of Epidemiology, Faculty of Veterinary Medicine University of Tehran Tehran Iran
- 700 1_
- $a Mirzaei, Sepideh $u Department of Biology, Faculty of Science Islamic Azad University, Science and Research Branch Tehran Iran
- 700 1_
- $a Bokaie, Saied $u Department of Food Hygiene and Quality Control, Division of Epidemiology, Faculty of Veterinary Medicine University of Tehran Tehran Iran
- 700 1_
- $a Bigham, Ashkan $u Institute of Polymers, Composites and Biomaterials - National Research Council (IPCB-CNR) Naples Italy
- 700 1_
- $a Makvandi, Pooyan $u Istituto Italiano di Tecnologia, Center for Materials Interfaces Pontedera, Pisa Italy $1 https://orcid.org/0000000324560961
- 700 1_
- $a Rabiee, Navid $u School of Engineering, Macquarie University Sydney New South Wales Australia
- 700 1_
- $a Thakur, Vijay Kumar $u School of Engineering University of Petroleum & Energy Studies (UPES) Dehradun Uttarakhand India $u Biorefining and Advanced Materials Research Center, Scotland's Rural College (SRUC) Edinburgh UK
- 700 1_
- $a Kumar, Alan Prem $u NUS Centre for Cancer Research (N2CR) Yong Loo Lin School of Medicine, National University of Singapore Singapore Singapore $u Department of Pharmacology Yong Loo Lin School of Medicine, National University of Singapore Kent Ridge Singapore
- 700 1_
- $a Sharifi, Esmaeel $u Department of Tissue Engineering and Biomaterials School of Advanced Medical Sciences and Technologies, Hamadan University of Medical Sciences Hamadan Iran $1 https://orcid.org/0000000334003106
- 700 1_
- $a Varma, Rajender S $u Regional Center of Advanced Technologies and Materials Czech Advanced Technology and Research Institute, Palacky University Olomouc Czech Republic
- 700 1_
- $a Aref, Amir Reza $u Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Harvard Medical School Boston Massachusetts USA $u Xsphera Biosciences Inc. Boston Massachusetts USA
- 700 1_
- $a Wojnilowicz, Marcin $u Commonwealth Scientific and Industrial Research Organisation (CSIRO) Manufacturing Clayton Victoria Australia $u Monash Institute of Pharmaceutical Sciences Parkville Victoria Australia $1 https://orcid.org/0000000264806615
- 700 1_
- $a Zarrabi, Ali $u Department of Biomedical Engineering, Faculty of Engineering and Natural Sciences Istinye University Istanbul Turkey $1 https://orcid.org/0000000303911769
- 700 1_
- $a Karimi-Maleh, Hassan $u School of Resources and Environment, University of Electronic Science and Technology of China Chengdu PR China $u Department of Chemical Engineering Quchan University of Technology Quchan Iran $u Department of Chemical Sciences, University of Johannesburg, Doornfontein Campus Johannesburg South Africa
- 700 1_
- $a Voelcker, Nicolas H $u Commonwealth Scientific and Industrial Research Organisation (CSIRO) Manufacturing Clayton Victoria Australia $u Monash Institute of Pharmaceutical Sciences Parkville Victoria Australia $u Melbourne Centre for Nanofabrication Victorian Node of the Australian National Fabrication Facility Clayton Victoria Australia
- 700 1_
- $a Mostafavi, Ebrahim $u Stanford Cardiovascular Institute, Stanford University School of Medicine Stanford California USA $u Department of Medicine Stanford University School of Medicine Stanford California USA $1 https://orcid.org/0000000339585002
- 700 1_
- $a Orive, Gorka $u NanoBioCel Research Group, School of Pharmacy University of the Basque Country (UPV/EHU) Vitoria-Gasteiz Spain $u University Institute for Regenerative Medicine and Oral Implantology-UIRMI(UPV/EHU-Fundación Eduardo Anitua) Vitoria-Gasteiz Spain $u Bioaraba, NanoBioCel Research Group Vitoria-Gasteiz Spain $u Singapore Eye Research Institute Singapore $1 https://orcid.org/000000020773300X
- 773 0_
- $w MED00209077 $t Bioengineering & translational medicine $x 2380-6761 $g Roč. 8, č. 1 (2023), s. e10325
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36684100 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230413 $b ABA008
- 991 __
- $a 20230421100140 $b ABA008
- 999 __
- $a ok $b bmc $g 1922847 $s 1189483
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2023 $b 8 $c 1 $d e10325 $e 20220913 $i 2380-6761 $m Bioengineering & translational medicine $n Bioeng Transl Med $x MED00209077
- LZP __
- $a Pubmed-20230413
